Galectin Therapeutics Inc. (GALT)

[biotech2010]

That's an interesting perspective on where the drug would be effective, I haven't read anything about it until you mentioned it.

This is the home stretch for GALT as a speculative investment with huge potential, all long term shareholders understand that if the September results are not good the company is most likely done as the cost of the money to continue would be hugely dilutive.

On the other hand, I believe they already know there is a very high probability of meeting expectation on this shorter trial, they would not have done the design in this manner unless they had supporting Phase 1 data that made it a good choice.